---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-086410"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:50:42.805048+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BiomX reports Q3 net loss $7.9M, cash $23.4M, BX004 Part 2 data expected this month

## Summary
- Net loss for Q3 2023 was $7.9 million, compared to $6.8 million for Q3 2022.
- Cash and equivalents stood at $23.4M as of Sep 30, 2023, down from $34.3M at Dec 31, 2022.
- Part 2 data from Phase 1b/2a trial of BX004 for cystic fibrosis expected later in November 2023.
- In August 2023, BX004 received FDA Fast Track designation for chronic respiratory infections in CF patients.
- Board appointed Edward L. Williams, former executive at Ascendis, Novo Nordisk, and Novartis, in October 2023.

## SEC filing metadata
- accession: 0001213900-23-086410
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/0001213900-23-086410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/ea188340-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-086410
- JSON: https://secwatch.observer/filing/0001213900-23-086410.json
- Plain text: https://secwatch.observer/filing/0001213900-23-086410.txt

## Key facts
- Earnings Releases
  BiomX Inc. reported financial results for for the third quarter ended September 30, 2023.
  - Period: for the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, BiomX Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/0001213900-23-086410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.